| Date | Time | Source | Announcement |
|---|---|---|---|
| 12 Nov 2001 | 07:00 AM | Research Update | |
| 01 Nov 2001 | 02:52 PM | Director Shareholding | |
| 15 Oct 2001 | 07:00 AM | Research Update | |
| 02 Oct 2001 | 11:00 AM | Termination of collaboration | |
| 12 Sep 2001 | 09:34 AM | Holding in Company | |
| 06 Sep 2001 | 10:31 AM | Hldg in Co/D. Shareholding | |
| 01 Aug 2001 | 07:01 AM | Interim Results | |
| 27 Jul 2001 | 04:39 PM | Notice of Results | |
| 10 Jul 2001 | 10:41 AM | Research Update | |
| 26 Jun 2001 | 01:44 PM | Statement re Patent | |
| 29 May 2001 | 05:28 PM | Holding in Company | |
| 29 May 2001 | 02:19 PM | Director Shareholding | |
| 29 May 2001 | 01:09 PM | Appointment | |
| 02 May 2001 | 05:56 PM | Additional Listing | |
| 24 Apr 2001 | 11:02 AM | Re Techmark Index | |
| 17 Apr 2001 | 04:20 PM | Completion of Fund Raising | |
| 17 Apr 2001 | 01:55 PM | Document regarding Listing Particulars | |
| 17 Apr 2001 | 07:00 AM | Results of EGM &Equity Issues | |
| 27 Mar 2001 | 07:00 AM | Successful patent application | |
| 12 Mar 2001 | 05:10 PM | Director Shareholding | |
| 12 Mar 2001 | 07:01 AM | Corporate Action | |
| 12 Mar 2001 | 07:01 AM | Full List/Placing& Open Offer | |
| 14 Feb 2001 | 03:59 PM | Additional Listing | |
| 13 Feb 2001 | 10:48 AM | Appointment | |
| 05 Feb 2001 | 07:00 AM | Acquisition of Technology | |
| 01 Feb 2001 | 04:35 PM | Access to Antibody Technology | |
| 26 Jan 2001 | 07:00 AM | Preliminary Results 2000 | |
| 22 Jan 2001 | 07:00 AM | Agreement with AHP Signed | |
| 02 Jan 2001 | 05:13 PM | Board Appointment | |
| 02 Jan 2001 | 07:13 AM | TroVax into Clinical Trials | |
| 13 Dec 2000 | 07:00 AM | Collaboration with Valentis | |
| 04 Dec 2000 | 07:00 AM | New Technology Developed | |
| 06 Nov 2000 | 07:00 AM | First Clinical Trials | |
| 16 Oct 2000 | 07:00 AM | Ethical Approval for Trovax | |
| 28 Sep 2000 | 09:53 AM | Director Shareholding | |
| 26 Sep 2000 | 07:30 AM | Bioinformatics Collaboration | |
| 23 Aug 2000 | 11:51 AM | Employee Share Options | |
| 17 Aug 2000 | 04:17 PM | Additional Listing | |
| 16 Aug 2000 | 07:00 AM | Interim Results 2000 | |
| 15 Aug 2000 | 05:48 PM | Additional Listing | |
| 15 Aug 2000 | 11:02 AM | Additional Listing | |
| 15 Aug 2000 | 07:00 AM | Research Update | |
| 10 Aug 2000 | 07:00 AM | Re Successful Fund Raising | |
| 08 Aug 2000 | 12:40 PM | Additional Listing | |
| 07 Aug 2000 | 01:25 PM | Statement re Press Comment | |
| 26 Jun 2000 | 08:21 AM | Research Update | |
| 06 Jun 2000 | 07:00 AM | Agreement | |
| 18 May 2000 | 11:05 AM | Agreements Signed, etc | |
| 02 May 2000 | 11:14 AM | Therapeutic Genes for Treatment of Cancer Acquired | |
| 31 Mar 2000 | 01:27 PM | Directors' Notification of Dealing in Shares |
Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.
Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.
Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.